Impact of Age or Sex on Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Participants with Moderate-to-Severe Acne
Main Article Content
Keywords
Pediatric, Adult, Acne, Male, Female, Retinoid, BPO, Adapalene, Clindamycin, Antibiotic, Combination
Abstract
Introduction: IDP-126 (clindamycin phosphate 1.2%/benzoyl peroxide [BPO] 3.1%/adapalene 0.15%) polymeric mesh gel is the first triple-combination, fixed-dose topical acne treatment in development. IDP-126 demonstrated superior efficacy to vehicle and component dyads, with good safety/tolerability, in a phase 2 and two phase 3 studies of participants with moderate-to-severe acne. The objective of this analysis was to assess the impact of age or sex on efficacy and safety/tolerability of IDP-126 gel.
Methods: This post hoc analysis evaluated effect of age or sex on efficacy/safety of IDP-126 using data pooled from two phase 3, double-blind, randomized, 12-week studies (NCT04214639, N=183; NCT04214652, N=180). Participants aged ≥9 years with moderate-to-severe acne were randomized 2:1 to once-daily IDP-126 gel or vehicle gel. Data were analyzed by age (pediatric [9-17 years]: n=178; adult [≥18 years]: n=185) or sex (females: n=212; males: n=151). Endpoints included ≥2-grade reduction from baseline in Evaluator’s Global Severity Score and clear/almost clear skin (treatment success) and least-squares mean percent change from baseline in inflammatory and noninflammatory lesion counts. Treatment-emergent adverse events (TEAEs) were also assessed.
Results: At week 12, over half of pediatric and almost half of adult IDP-126-treated participants achieved treatment success (52.7% and 45.9%, respectively) versus one-fourth with vehicle (24.0% and 23.5%; P<0.01, both). Results by sex were similar (IDP‑126 vs vehicle: females: 53.7% vs 23.0%; males: 43.1% vs 24.6%; P<0.05, both). IDP‑126 provided >70% reductions in inflammatory and noninflammatory lesions in all subgroups, versus 41%-63% with vehicle (P≤0.001, all). Differences between sex or age groups were not statistically significant. Most TEAEs were of mild-moderate severity in all groups.
Conclusions: Fixed-dose, triple-combination IDP-126 gel was efficacious and well tolerated in participants with moderate-to-severe acne, regardless of age or sex, with approximately half of participants achieving clear/almost clear skin.
Funding: Ortho Dermatologics
References
2. Stein Gold L. J Drugs Dermatol. 2019;18(12):1218-1225.
3. Cook-Bolden F. J Drugs Dermatol. 2020;19(1):78-85.
4. Hester C, et al. Pediatr Dermatol. 2016;33(1):49-55.
5. Kraft J and Freiman A. CMAJ. 2011; 183(7):E430-435.
6. Zeichner JA, et al. J Clin Aesthet Dermatol. 2017;10(1):37-46.
7. Stein Gold L, et al. Am J Clin Dermatol. 2022;23(1):93-104.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.